{"schema_version":"secwatch.filing_event.v1","accession":"0001613103-23-000032","form_type":"8-K","ticker":"MDT","cik":"0001613103","company_name":"Medtronic plc","filed_at":"2023-05-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.668084+00:00","generated_at":"2026-06-14T14:35:45.881418+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Medtronic Q4 revenue beats at $8.5B (+5.6%); raises dividend to $0.69 quarterly","bullets":["Q4 GAAP EPS $0.88 (-20% YoY); non-GAAP EPS $1.57 (+3%), ahead of expectations.","FY23 revenue $31.2B (-1.4% reported, +2.1% organic); FY organic growth guided 4.0-4.5%.","Dividend increased to $0.69/share quarterly ($2.76 annual); 46th consecutive annual increase.","Announced definitive agreement to acquire EOFlow Co. Ltd. (EOPatch tubeless insulin pump).","FY24 non-GAAP EPS guidance $5.00-$5.10; revenue positively impacted by FX ~$110-210M."],"urls":{"canonical":"https://secwatch.observer/filing/0001613103-23-000032","json":"https://secwatch.observer/filing/0001613103-23-000032.json","markdown":"https://secwatch.observer/filing/0001613103-23-000032.md","text":"https://secwatch.observer/filing/0001613103-23-000032.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1613103/000161310323000032/0001613103-23-000032-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1613103/000161310323000032/mdt-20230525.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T14:35:45.881418+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6c08adc25a2a8d4d403204c2b35bf047ad9620ec","claim":"Medtronic plc reported fiscal year 2023 results: revenue $31.227 billion, net income $3.758 billion, EPS $2.82.","evidence_excerpt":"non-GAAP diluted EPS were $2.093 billion and $1.57, respectively, both increases of 3%. Fiscal Year 2023 (FY23) Financial Results Medtronic reported FY23 worldwide revenue of $31.227 billion, a decrease of 1.4% as reported and an increase of 2.1% on an organic basis. The FY23 organic revenue growth comparison excludes: • a $1.437 billion negative impact from foreign","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1613103/000161310323000032/0001613103-23-000032-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fiscal year 2023"},{"label":"Revenue","value":"$31.227 billion"},{"label":"Net income","value":"$3.758 billion"},{"label":"EPS","value":"$2.82"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"b7e617fba8b19249b1dc6b6fe1054c03b4cab0f0","claim":"Medtronic plc reported fourth quarter fiscal year 2023 results: revenue $8.5 billion, net income $1.179 billion, EPS $0.88.","evidence_excerpt":"Q4 revenue of $8.5 billion increased 5.6% as reported and organic, ahead of expectations • Q4 GAAP diluted EPS of $0.88 decreased 20%; non-GAAP diluted EPS of $1.57 increased 3% in the quarter, ahead of expectations","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1613103/000161310323000032/0001613103-23-000032-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter fiscal year 2023"},{"label":"Revenue","value":"$8.5 billion"},{"label":"Net income","value":"$1.179 billion"},{"label":"EPS","value":"$0.88"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}